The spatiotemporal progression of dopamine depletion in Parkinson's disease (PD)
provides a special model for assessing dopaminergic effects on neural systems with …

Apart from the typical motor symptoms, Parkinson's disease is characterized by a wide range
of different non-motor symptoms, which are highly prevalent in all stages of the disease and …

To evaluate the effects of the dopamine D2‐D3 agonist ropinirole in patients who developed
apathy after complete withdrawal from dopaminergic medication following successful …

Parkinson's disease is a neurodegenerative disorder involving the basal ganglia that results
in a host of motor and cognitive deficits. Dopamine-replacement therapy ameliorates some …

In this paper, the theoretical models of the molecularly imprinted polymer surface
microenvironment were investigated. S-Pramipexole was used as a model drug and its …

4-Alkenyl-2-dialkylaminothiazoles act as in–out dienes in [4+ 2] cycloaddition reactions with
nitroalkenes, furnishing 2-amino-6-nitro-4, 5, 6, 7-tetrahydrobenzothiazoles in moderate to …

Objective: This study aimed to systematically review the effects of currently prescribed
antiparkinson medication on cognition in patients with mild-to-moderate Parkinson's disease …

Subtle cognitive impairment can be detected in early Parkinson's disease (PD). In a
consecutive series of de novo, drug-naive PD patients, we applied stepwise regression …

Pramipexole is a non-ergot dopamine agonist shown to be efficacious in the treatment of
Parkinson's disease (PD). This review addresses the literature concerning pramipexole's …

In Parkinson's disease (PD) reduced dopaminergic activity in the mesocorticolimbic pathway
is implied in the pathophysiology of several non-motor symptoms related to mood …